Request Trial
pharma-istock-598676126-kadmy-
kadmy / iStockphoto.com
9 May 2017Americas

Generic companies ask district court to dismiss Takeda competition claims

Four generic companies have pushed a district court to dismiss competition allegations against them, stating that the latest amendments made by American Sales Company in a class action complaint are “purely cosmetic” and add no new factual allegations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
26 February 2026   As the US Supreme Court prepares to hear arguments in the Hikma and Amarin dispute, the case has drawn a broad coalition of industry support—including the US government and a co-author of the Hatch-Waxman Act itself.
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026   In a decision with implications for biotechnology licensing and pharmaceutical manufacturing, the Ninth Circuit has rejected a ‘sweeping’ royalty trigger from a lower court.
Americas
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
25 February 2026   The Danish company is contending with fierce competition, a clinical trial setback and a UK boost to its main rival, while making new moves to enforce its weight-loss-drug IP.


Editor's picks

Eli Lilly escapes $278m payout in biotech licensing dispute
Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026

Editor's picks

Americas
Eli Lilly escapes $278m payout in biotech licensing dispute
26 February 2026
Asia
AstraZeneca partners with Chinese firm ahead of next obesity race
5 February 2026
Americas
The quantum advantage: IP considerations for the next generation of life sciences innovation
27 January 2026
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026
Americas
Bayer enters COVID-19 vaccine row with three suits against major drugmakers
8 January 2026
Americas
SCOTUS shuts the door on Entresto ‘after-arising technology’ review
17 December 2025

More features

SCOTUS flooded with briefs calling for reversal of ‘skinny label’ ruling
Eli Lilly escapes $278m payout in biotech licensing dispute
Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices
Wiggin’s new litigation partner deepens ‘technically complex’ offer
Could everyday hospital equipment be the next defence against counterfeit medicines?
BioNTech fires shots at Moderna's next-generation vaccine
Mintz gains ex-Winston & Strawn partner and ITC expert
Abbott unit defends European protection for heart valve ‘cuff’ design